As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

As­traZeneca, No­vo Nordisk, and Sanofi won an ap­peals court win on Mon­day, as the US Court of Ap­peals for the Third Cir­cuit found that the com­pa­nies can­not be forced to pro­vide 340B-dis­count­ed drugs pur­chased by hos­pi­tals from an un­lim­it­ed num­ber of com­mu­ni­ty and spe­cial­ty phar­ma­cies.

“Le­gal du­ties do not spring from si­lence,” the de­ci­sion says as the court makes clear that the fed­er­al gov­ern­ment’s in­ter­pre­ta­tion of the “sup­posed re­quire­ment” that the 340B pro­gram com­pels drug­mak­ers to sup­ply their dis­count­ed drugs to an un­lim­it­ed num­ber of con­tract phar­ma­cies is not cor­rect, not­ing:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER